{"title":"嗜酸乳杆菌增强四联疗法患者幽门螺杆菌感染临床症状的缓解","authors":"Hongyan Cai, X. Si","doi":"10.37290/ctnr2641-452x.21:125-130","DOIUrl":null,"url":null,"abstract":"The relief from clinical symptoms of Helicobacter pylori infection caused by Lactobacillus acidophilus treatment was analyzed by a 13C-urea breath test. To this end, 200 patients diagnosed with Helicobacter pylori infection were divided into two equal groups of 100 patients, designated as the control and study groups, respectively. The control group received conventional quadruple therapy that included enteric-coated esomeprazole magnesium tablets, amoxicillin, clarithromycin, and colloidal pectin bismuth for 2 weeks. The study group, in addition to the conventional quadruple therapy, received Lactobacillus acidophilus tablets orally for 2 weeks. The Helicobacter pylori eradication rate (P < 0.05) and total effective rate (P < 0.05) of the study group were higher than the control group. The incidence of adverse reactions including acid reflux, upper abdom¬inal pain, abdominal fullness, and vomiting in the study group was lower (P < 0.05) than the control group. There was no statistically significant difference (P > 0.05) in the levels of tumor nuclear factor-α, high sensitivity C-reaction protein, and interlukin-6 between two groups before treatment. However, the level of these indicators in the study group after treatment was lower than that in the control group. Similarly, there was no statistically significant difference in CD3+, CD4+, CD8+, or CD4+/CD8+ between the two groups before treatment. However, the level of CD3+, CD4+, and CD4+/CD8+ after treatment was significantly higher, while CD8+ was significantly lower in the study group. In conclusion, Lactobacillus acidophilus treat¬ment exhibits a high eradication rate of Helicobacter pylori with good safety and relief from Helicobacter pylori-associated clinical symptoms.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lactobacillus acidophilus Enhances Relief from Clinical Symptoms of Helicobacter pylori Infection in Patients on Quadruple Therapy\",\"authors\":\"Hongyan Cai, X. Si\",\"doi\":\"10.37290/ctnr2641-452x.21:125-130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The relief from clinical symptoms of Helicobacter pylori infection caused by Lactobacillus acidophilus treatment was analyzed by a 13C-urea breath test. To this end, 200 patients diagnosed with Helicobacter pylori infection were divided into two equal groups of 100 patients, designated as the control and study groups, respectively. The control group received conventional quadruple therapy that included enteric-coated esomeprazole magnesium tablets, amoxicillin, clarithromycin, and colloidal pectin bismuth for 2 weeks. The study group, in addition to the conventional quadruple therapy, received Lactobacillus acidophilus tablets orally for 2 weeks. The Helicobacter pylori eradication rate (P < 0.05) and total effective rate (P < 0.05) of the study group were higher than the control group. The incidence of adverse reactions including acid reflux, upper abdom¬inal pain, abdominal fullness, and vomiting in the study group was lower (P < 0.05) than the control group. There was no statistically significant difference (P > 0.05) in the levels of tumor nuclear factor-α, high sensitivity C-reaction protein, and interlukin-6 between two groups before treatment. However, the level of these indicators in the study group after treatment was lower than that in the control group. Similarly, there was no statistically significant difference in CD3+, CD4+, CD8+, or CD4+/CD8+ between the two groups before treatment. However, the level of CD3+, CD4+, and CD4+/CD8+ after treatment was significantly higher, while CD8+ was significantly lower in the study group. In conclusion, Lactobacillus acidophilus treat¬ment exhibits a high eradication rate of Helicobacter pylori with good safety and relief from Helicobacter pylori-associated clinical symptoms.\",\"PeriodicalId\":10976,\"journal\":{\"name\":\"Current Topics in Nutraceutical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Topics in Nutraceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.37290/ctnr2641-452x.21:125-130\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Topics in Nutraceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37290/ctnr2641-452x.21:125-130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Lactobacillus acidophilus Enhances Relief from Clinical Symptoms of Helicobacter pylori Infection in Patients on Quadruple Therapy
The relief from clinical symptoms of Helicobacter pylori infection caused by Lactobacillus acidophilus treatment was analyzed by a 13C-urea breath test. To this end, 200 patients diagnosed with Helicobacter pylori infection were divided into two equal groups of 100 patients, designated as the control and study groups, respectively. The control group received conventional quadruple therapy that included enteric-coated esomeprazole magnesium tablets, amoxicillin, clarithromycin, and colloidal pectin bismuth for 2 weeks. The study group, in addition to the conventional quadruple therapy, received Lactobacillus acidophilus tablets orally for 2 weeks. The Helicobacter pylori eradication rate (P < 0.05) and total effective rate (P < 0.05) of the study group were higher than the control group. The incidence of adverse reactions including acid reflux, upper abdom¬inal pain, abdominal fullness, and vomiting in the study group was lower (P < 0.05) than the control group. There was no statistically significant difference (P > 0.05) in the levels of tumor nuclear factor-α, high sensitivity C-reaction protein, and interlukin-6 between two groups before treatment. However, the level of these indicators in the study group after treatment was lower than that in the control group. Similarly, there was no statistically significant difference in CD3+, CD4+, CD8+, or CD4+/CD8+ between the two groups before treatment. However, the level of CD3+, CD4+, and CD4+/CD8+ after treatment was significantly higher, while CD8+ was significantly lower in the study group. In conclusion, Lactobacillus acidophilus treat¬ment exhibits a high eradication rate of Helicobacter pylori with good safety and relief from Helicobacter pylori-associated clinical symptoms.
期刊介绍:
Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products.
To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine.
The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.